Physician
Gastroenterology
Dr. Stephen A. Harrison, MD
|
|
Give Review
Stephen A. Harrison, MD is an expert in the field of Gastroenterology. He went to University of Mississippi School of Medicine. Stephen Harrison is a published physician. He has 98 publications published. The most current publication "Interscalene anesthesia for shoulder arthroscopy in a community-sized military hospital."
Publications
- Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
- Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.
- The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic.
- Controversies in the Diagnosis and Management of NAFLD and NASH.
- Nutrition in cirrhosis and chronic liver disease.
- Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?
- Review of treatment options for nonalcoholic Fatty liver disease.
- NAFLD: Predictive value of ALT levels for NASH and advanced fibrosis.
- Is it time to write a prescription for coffee? Coffee and liver disease.
- Vitamin D and NAFLD: Is it more than just an association?
- Intensified peginterferon ?-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipo...
- Insulin resistance in chronic hepatitis C: the search for effective drug treatment continues.
- Hepatitis C virus infection and nonalcoholic steatohepatitis.
- Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
- Management of anemia in patients receiving protease inhibitors.
- Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, p...
- Olanzapine and Benztropine as a Cause of Ischemic Colitis in a 27-year-old Man.
- Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis.
- MiraLAX is not as effective as GoLytely in bowel cleansing before screening colonoscopies.
- Insulin sensitizers in nonalcoholic steatohepatitis.
- Insulin resistance and hepatitis C: an evolving story.
- Nivalenol-type populations of Fusarium graminearum and F. asiaticum are prevalent on wheat in southern Louisiana.
- Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospec...
- Management of hepatitis C virus genotype 4: recommendations of an international expert panel.
- Integration of Lead Optimization with Crystallography for a Membrane-Bound Ion Channel Target: Discovery of a New Class of AMPA Receptor Positive Allosteric Modulators.
- Manifestations of chronic hepatitis C virus infection beyond the liver.
- Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.
- Nonalcoholic fatty liver disease: is it all in the genes?
- Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
- Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
- Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution?
- Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, op...
- A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
- Effect of weight loss on nonalcoholic fatty liver disease.
- NASH and HCC.
- Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
- Same day endoscopy and percutaneous liver biopsy: safety and cost-effectiveness.
- Hepatitis C virus: a critical appraisal of approaches to therapy.
- Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
- Inflammatory bowel disease: thinking outside of the intestines (Part 1).
- Inflammatory bowel disease: thinking outside of the intestines (Part 2).
- Current and emerging therapies in nonalcoholic fatty liver disease.
- Hepatitis C virus and insulin resistance/diabetes mellitus.
- Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment.
- HCV in patients with end-stage renal disease.
- HCV replication and statin pleotropism: an adjuvant treatment panacea?
- Insulin resistance in chronic hepatitis C, genotypes 1 and 4: the unfortunate reality.
- Diagnosis and therapy of nonalcoholic steatohepatitis.
- Abnormal liver tests and fatty liver on ultrasound.
- Current treatments in nonalcoholic steatohepatitis.
- Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass.
- Small molecule and novel treatments for chronic hepatitis C virus infection.
- H. pylori and platelet counts.
- A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
- Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase.
- Impact of obesity on treatment of chronic hepatitis C.
- Correlation between insulin resistance and hepatitis C viral load.
- Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.
- New treatments for nonalcoholic fatty liver disease.
- Liver disease in patients with diabetes mellitus.
- Diabetic hepatosclerosis: diabetic microangiopathy of the liver.
- New advances in evaluation and management of patients with polycystic liver disease.
- Steatosis and chronic hepatitis C infection: mechanisms and significance.
- Extrahepatic manifestations of hepatitis C.
- Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.
- Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention.
- Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease.
- Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
- The role of vitamin E and C therapy in NASH.
- Pharmacologic management of nonalcoholic fatty liver disease.
- Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related.
- Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
- The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.
- Orlistat in the treatment of NASH: a case series.
- A new approach to therapy for hepatocellular carcinoma?
- Nonalcoholic steatohepatitis: what we know in the new millennium.
- Fat and the liver--a molecular overview.
- An assessment by the Statin Liver Safety Task Force: 2014Â update.
- Comparative Systems Biology Reveals Allelic Variation Modulating Tocochromanol Profiles in Barley (Hordeum vulgare L.).
- Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine.
- Quantitative trait loci in the Ogle/TAM O-301 oat mapping population controlling resistance to Puccinia coronata in the field.
- Occupational therapy task observation scale (OTTOS): a rapid method for rating task group function of psychiatric patients.
- Interscalene anesthesia for shoulder arthroscopy in a community-sized military hospital.
- The neural correlates of visual working memory encoding: a time-resolved fMRI study.
- Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime.
- Training improves multitasking performance by increasing the speed of information processing in human prefrontal cortex.
- High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
- The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A P...
- Nonalcoholic fatty liver disease.
- Peroxisome proliferator-activated receptors and hepatitis C virus.
- Validation of the non-alcoholic fatty liver disease activity score.
- A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.
- Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.
- R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
- Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
- Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.
- Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease.
Schools
Univ Of Ms Sch Of Med
Doctors Specialties
- Gastroenterology
Accepted Insurances
Education
-
San Antonio Uniformed Services Health Education Consortium -
University of Mississippi School of Medicine
Hospital
-
Wilford Hall Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Jonathon W. Schwake, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph E. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Zarema Singson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alfredo Espinoza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luis J. Acosta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura A. Rosenkranz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul B. Lamb, MD |
|
Dr. Julio A. Gutierrez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles W. Randall, MD |
|
|
Dr. Komaranahalli P. Ganeshappa, MD
This Doctor is OpenDoctor Recommended.
|